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Experimental Section
Reagents and Standards
Authentic standards of MDMA, ketamine, and methoxyphenamine were purchased from Sigma Chemical Co. HPLC grade acetonitrile (Lab-scan Analytical Sciences), absolute ethanol (CSR Ltd.), methanol (Lab-scan Analytical Sciences), diethyl ether (Labscan Analytical Sciences), and KBr (spectroscopic grade, BDH Laboratory Supplies) were obtained commercially and used as received. Deionized water from a Millipore Milli-Q System was used. Ammonium molybdate solution (7% w/v) used for the phosphate test was prepared by dissolving 7 g of ammonium molybdate (Merck) in 70 mL of deionized water and 30 mL of concentrated nitric acid (Lab-scan Analytical Sciences).
Infrared Spectroscopy
Solid-phase infrared spectra were obtained on a Perkin-Elmer Spectrum One FTIR as KBr pellets.
High-Performance Liquid Chromatography (HPLC)
The concentrations of MDMA and ketamine were determined by a Shimadzu model LC-10AD high-performance liquid chromatograph (HPLC) interfaced with Shimadzu model SPD-M10AVP diode array detector (DAD), using an Alltima C18 column (5 m, 150 by 4.6 mm) (Alltech Associates Inc.) with a CH 3 CN:H 2 O mixture (1:3 v/v) as the mobile phase. The absorbance of MDMA and ketamine was measured at 218 nm with methoxyphenamine as the internal standard.
Gas Chromatograph/Mass Spectrometry (GC-MS)
GC-MS analyses were performed using a Hewlett-Packard (HP) series 6890 GC interfaced to a HP 5972 series mass selective detecter (MSD). A cross-linked phenylmethyl siloxane capillary column was used (Hewlett-Packard HP-1MS, 0.25 mm by 30 m, 0.25 m in thickness) with ultra-high-purity-grade helium gas as the carrier gas (constant flow rate, 1.0 mL/min). The typical temperature settings were as follows: injector port, 260°C; initial column temperature, 70°C; hold time, 1 min; temperature ramp, 30°C/min to 180°C; then 7°C/min to 300°C and final temperature, 300°C; hold time, 10 min. The mass spectra were compared with a commercially available NIST library.
Electrospray Ionization-Mass Spectrometry (ESI-MS)
ESI-MS analyses were performed on a Bruker ESQUIRE-LC Ion-trap LC/MS (n) system equipped with an electrospray ionization source. The spectrometer was comprised of an octapole and ion trap mass analyzer with nitrogen as drying gas. The temperature of the drying gas was 300°C and the flow rate was 4 L/min. Nitrogen was also applied as the sheath (nebulizing) gas. The sample was dissolved in a mixture of MeOH and water (1:1 v/v), and the sample flow was set at 4 L/min. The electrospray voltage was set at 4 kV for the capillary, and Ϫ400 V for the end plate. The multiplier voltage was 1.6 kV and the dynode at 7 kV. To obtain good peak intensities for the lens system, the capillary exit was maintained at 45 V, the Skimmer 1 at 15 V, the capillary exit offset at 30 V, and the two exit lenses at Ϫ5 and Ϫ60 V, respectively. The direct current (dc) offset of the octapole was set at 2 V, and the radio frequency amplitude at 120 V.
Sample Preparations
HPLC quantitations of MDMA and ketamine were based on three-point calibration curves established using authentic standards of MDMAиHCl (0.2 to 1.6 mg/mL) and ketamineиHCl (1 to 15 mg/mL), respectively, in the presence of methoxyphenamine (2 mg/mL) dissolved in a CH 3 CN:H 2 O mixture (1:3 v/v) (mobile phase).
The tablets were ground into powder. About 20 mg of powder was accurately weighed into a 10-mL volumetric flask followed by the addition of 1.0 mL of methoxyphenamineиHCl (2 mg/mL) in the mobile phase and was made up to mark using the mobile phase. The mixture was sonicated for about 30 min, filtered through a 0.45-m pore-size nylon membrane, and diluted five times using the mobile phase into an LC vial before injection.
For GC-MS analyses, the tablets were ground into powder, and about 5 mg of the homogenous powder were extracted with 1 mL of absolute ethanol and were filtered through a 0.45-m pore-size nylon membrane into a GC vial.
Results and Discussion
In most of the cases received by our laboratory, the tablets were embossed with logos (e.g., Diamond, Mitsubishi) or alphanumeric characters (e.g., P, CK, CC, HQ, 88, B29) and were also dyed with various colors. Before 2000, most of the seized ecstasy tablets were found to contain only a single active ingredient such as MDMA, 3,4-methylenedioxyamphetamine (MDA), 1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB), or 3,4-methylenedioxyethylamphetamine (MDEA), and tablets containing a mixture of MDMA and MDEA were found only occasionally. However, since 2000 the composition of the ecstasy tablets has undergone drastic changes, with tablets now often containing complex chemical compositions. Of note, increasing numbers of ecstasy tablets were found to contain nonamphetamine-type ingredients such as ketamine and caffeine. In some tablets, MDMA was not present, but methamphetamine (MA) was instead used as the principal ingredient. In addition, for these MA tablets, different combinations of other drug ingredients such as ketamine, caffeine, diazepam, phenobarbital, chlorpromazine, and imipramine were commonly encountered.
The more than 600,000 tablets received in our laboratory in the years 2000 and 2001 were categorized into 212 types according to their physical appearances and the types of amphetamines found. Chemical analysis of these tablets indicated that some with similar physical appearances had different chemical compositions. A typical example is illustrated in Table 1 , showing a relationship between analytical profiles and the commonly encountered rectangular tablets with the "CC" marking. For the samples having a similar orange color and physical dimensions (Entries 1, 2, and 3), either MDMA (Entry 1) or MA (Entries 2 and 3) were found as the active ingredient. In addition, even for similar orange "CC" tablets containing MA as the active ingredient, different combinations with other nonamphetamine components such as diazepam and phenobarbital (Entry 2) and ketamine and caffeine (Entry 3) were detected. On the other hand, different-colored tablets bearing similar markings may contain similar chemical ingredients (e.g., compare Entries 1 and 7, Entries 3 and 5).
In some cases, ecstasy tablets with different physical characteristics contained similar constituents. Typical examples are the MDMA tablets with markings "CC," "88," and "P," shown in Table 2 . Although they have different logos/markings, sizes, shapes, and/or colors, all of them were found to have similar MDMA contents (about 50%). Furthermore, ketamine was detected in all of these tablets. Thus, general physical characteristics of the tablets do not bear a direct relationship with their inherent chemical compositions. In fact, the uses of several dyes (e.g., yellow, blue, and red) and metal dies with different shapes, logos, or letters (e.g., rectangular CC, circular 88, and AP) were found at a local ecstasy tablet-manufacturing scene. This indicates that different combinations of dyes and metal tablet dies are likely to be employed for ecstasy manufacturing even at a single site (personal communication). In order to collect systematic information for drug intelligence, we set forth to establish a protocol for chemical profiling of the ecstasy seizures.
To begin our study, the ecstasy tablets were first classified into the four groups according to their principal ingredient: (1) MDMA, (2) MA (methamphetamine), (3) MDA, or (4) amphetamine. As noted earlier, there were a total of 212 different types of ecstasy tablets. According to basis of these relative abundances, MDMA constituted the major drug type for ecstasy abuse in Hong Kong, and hence our study focused on the chemical profiling of MDMA tablets.
Chemical Profiling
Although a majority of the ecstasy samples seized in Hong Kong were MDMA-only tablets, the number of tablets containing ketamine in addition to MDMA rose. In 2000, around 12% of the total MDMA cases were found to contain ketamine in addition to MDMA (i.e., 125 cases out of a total of 1,023 cases). However, the figure rose significantly to 42% in 2001 (i.e., 413 cases out of 973 cases). A similar trend (ca. three-fold increase) was also observed for MA tablets: MA tablets also containing ketamine rose from 23% (i.e., 59 cases out of 255 cases) in 2000 to 83% (i.e., 653 cases out of 780 cases) in 2001.
For the MDMA tablets seized in 2001, those containing ketamine were found to have a comparable percentage of MDMA content to that of the MDMA-only tablets. For instance, examination of 137 cases (with a total of 1893 tablets) of the orange rectangular tablets with the same "CC" logo indicated that the tablets contained 45 to 51% (weight by weight) of MDMA and 7 to 13 % (weight by weight) of ketamine. The percent MDMA is close to the average MDMA content of 46% found in the MDMA-only tablets. The average MDMA content was determined from a population of 31,508 tablets MDMA-only tablet obtained in 333 cases during the year 2001. This similarity in the percent MDMA content suggested that similar amounts of MDMA were used to make up a tablet with similar size and weight irrespective of whether or not ketamine is added. Therefore, the addition of ketamine in such tablets may not only be used to replace part of excipients or inert substances but also be used as an adulterant probably to enhance the drug effects of MDMA.
Impurities Profiling
Upon close scrutiny of the chemical compositions of MDMA tablets, we detected, in some cases, trace impurities that were either structurally related to MDMA or its precursors. These trace impurities, which were either starting materials, intermediates, or manufacturing by-products, can serve as markers characterizing the synthetic route(s) employed for MDMA production. Collection of the impurity profiles could generate useful intelligence information to trace the origin of the tablets and possibly the synthetic route(s) of MDMA currently found in the blackmarket.
As an example, the GC-MS result of an MDMA tablet is depicted in Fig. 3 . The total ion chromatogram showed two prominent peaks at R t ϭ 6.3 and 8.8 min, assignable to MDMA and caffeine, respectively. There are two partially overlapping peaks at R t ϭ ca. 5.9 min; their mass spectra correspond to 1-(3,4-methylenedioxyphenyl)-2-propanone (MDP2P) and 1-(3,4-methylenedioxyphenyl)-2-propanol (MDP), respectively. Furthermore, another peak at R t ϭ 5.5 min was confirmed to be 3,4-methylenedioxy-N-methylbenzylamine (MDB).
Several methods are known in the literature for the synthesis of MDMA (22, 23) , and those methods that use MDP2P as the key precursor are (i) Leuckart's reaction (24, 25) and (ii) reductive amination (26) (Fig. 4) . It is likely that the MDP detected in the MDMA tablets is a side product resulting from direct reduction of MDP2P with excess reductant (e.g., sodium cyanoborohydride) consistent with a typical reductive amination route being employed for the MDMA production. However, an alternative twostep reaction method has been identified by Liang (27) . This method involves the reaction of N-methylbenzylamine (as a substitute source for methylamine) with sodium cyanoborohydride and MDP2P to give N-benzyl-3,4-methylenedioxymethamphetamine, followed by reduction with hydrogen in the presence of palladium/carbon (by cleaving the benzyl group). In this case, production of a significant amount of the MDP as a side product was also reported.
The presence of MDB in the sample implies that piperonal was the precursor for making the MDMA via reductive amination of MDP2P (Eq 3, Fig. 4 
) (16). It is known that MDP2P can also be FIG. 3-Typical total ion chromatogram of MDMA tablets that contain impurities and other drugs: (1) 3,4-methylenedioxy-N-methylbenzylamine (MDB), (2) 1-(3,4-methylenedioxyphenyl)-2-propanol (MDP), (3) 3,4-methylenedioxyphenyl-2-propanone (MDP2P), (4) MDMA, (5) caffeine.
prepared by oxidation of isosafrole (ISOSAF) (23,25), 3,4-methylendioxymethylnitrostyrene (MDMNS) (28) (29) (30) or ␤-3,4-methylenedioxyphenyl-␣-methyl glycidic ester (31). Dal Cason has described how piperonal can serve as primary precursor for MDMNS (Eq 4, Fig. 4) (23) . Therefore, the co-existence of MDP and MDB together implies that the MDMA was derived from piperonal via MDMNS as intermediate to produce MDP2P. Subsequent reductive amination of MDP2P, via either a one-step (e.g., Na(CN)BH 4 /methylamine) or two-step reaction (27) , produces MDMA.
Among the 613 cases (with a total of 123,776 tablets) randomly taken for study in 2001, there were a total of 416 cases having been taken for GC-MS analyses. As laboratory policy, no GC-MS analysis was performed if a definitive FTIR matching of MDMA for a particular case was accomplished. Of the 416 cases taken for GC-MS analyses, a total of 341 cases were found to contain traces amounts of impurities such as 3,4-methylenedioxyphenyl-2-propanone (MDP2P), 3,4-methylenedioxyphenyl-2-propanol (MDP), 3,4-methylenedioxybenzylamine (MDB) and/or piperonal. The presence of these impurities strongly suggested that the MDMA found in Hong Kong in 2001 was predominantly synthesized via the key intermediate, MDP2P, which in turn was prepared from piperonal.
The comparison of the chemical profiles to link different cases is governed by two factors: (1) the resemblance of the correlation of two or more impurities/additives profiles, and (2) the frequency of particular profiles. As shown in Table 2 , there were a total of 1893 orange rectangular MDMA tablets marked "CC" from 137 cases. These tablets were first encountered in November 2000, and all of them were found to contain ketamine with impurities such as MDP2P, MDP, and piperonal frequently detected. Yet, irrespective of the physical and chemical similarities, these tablets could be further classified into three different groups according to their MDMA and ketamine contents ( Table 3 ). The total ion-chromatograms (TIC) of these three groups are depicted in Fig. 5 . In addition to the detection of the above-mentioned known impurities, a full comparison of the TIC profiles also showed high degrees of similarity among these three groups of MDMA tablets. These results collectively provided substantial evidence to suggest that even though these three groups of tablets could have associated with a common origin, they were probably produced at different times. Indeed, the cases involving these three batches of tablets were first received by our laboratory at different times As shown in Table 4 , orange circular tablets with an impressed logos "88" or "P" that were obtained from a total of 78 cases and 2 cases, respectively, were compared with the above-mentioned orange "CC" tablets. It is striking that they all contained the same major ingredients (i.e., MDMA and ketamine). Furthermore, impurities like MDP2P, MDP, and piperonal were also frequently detected. Added to this, the representative TIC profiles for tablets of "CC" and "88" also showed great resemblance (see Fig. 6 ). Apart from the above findings, the MDMA and ketamine contents (46 to 48% of MDMA and 8 to 9% of ketamine for "88" tablets, and 51% of MDMA and 9% of ketamine for "P" tablets) were similar to one group of the "CC" tablets (Entry 2, Table 3 ). Therefore, the similarity in the analytical profiles of these three different types of tablets, namely the tablets of orange rectangular "CC" and orange circular "88" and "P," suggested a reasonable linkage that they are likely to have associated with a common origin regardless of having different physical characteristics and being from different cases.
In another type of tablet with the impressed logo "HQ" on both sides and occurring in various colors, GC-MS analysis (Fig. 7) confirmed the presence of MDMA with a prominent peak at R t ϭ ca. 6.0 min. In addition to MDP at R t ϭ ca. 5.7 min, another small peak at R t ϭ 9.2 min was confirmed to be N-formyl-3,4-methylenedioxymethamphetamine (N-formyl-MDMA) by matching its mass spectrum with an authentic spectrum obtained from a NIST mass spectral library. N-Formyl-MDMA has been reported as a marker for the conversion of MDP2P to MDMA via the Leuckart reaction, which proceeds by reacting MDP2P with N-methylformamide and formic acid (Eq 2, Fig. 4) (26) .
In the past, MDMA found in the tablets was solely in the form of hydrochloride salt; however, a preliminary anion test for chloride on the above-referenced "HQ" tablets gave a negative result. Instead, a presumptive ion test for phosphate using a solution of am- 
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monium molybdate gave a yellow precipitate. With this information, we expanded our studies to elucidate the chemical structure of the suspected phosphate salt of MDMA.
MDMA Phosphate-An Unusual Salt of Illicit MDMA
After extracting the tablets with chloroform and evaporating the extracts to dryness over a steam bath, the sample was subjected to FTIR analyses. Detailed examination of the IR spectrum (Fig. 8) showed that the sample possessed virtually all the characteristic peaks of MDMA hydrochloride; however, all peaks in the range of 1300 to 850 cm Ϫ1 (attributed to the vibrational absorption of MDMA) were overlapped with some broad peaks. Comparing this region with the IR spectrum of disodium hydrogen phosphate (same region), these broad peaks appeared to be the stretching vibrations of (P ϭ O) and (P Ϫ O).
To confirm phosphate as being the salt of crystallization, the MDMA sample (MeOH/H 2 O ϭ 1:1) was analyzed by electrospray mass spectrometry. The mass spectrum (Fig. 9) showed two intense peaks at m /z ϭ 485 and 194. The former peak was assigned as [(HMDMA) 2 (H 2 PO 4 )] ϩ (1), while the latter was assigned to HMDMA ϩ . The MS/MS analysis of the peak at m/z ϭ 485 is shown as an inset in Fig. 9 ; the peak at m /z ϭ 387 is consistent with the formulation of [(HMDMA)(MDMA)] ϩ , arising from the loss of a H 3 PO 4 from 1. Figure 10 showed the electrospray ion mass spectrum of the sample in negative polarity; the peak at m /z ϭ 97 corresponds to the H 2 PO 4 Ϫ anion. (4) are possible. One way to ascertain the most plausible formulation is to determine the MDMA content of a purified phosphate salt obtained from the tablets. Assuming 100% chemical purity, the expected MDMA content in 2, 3, and 4 are 85.6, 79.8, and 66.3%, respectively. Prior to LC analysis, the samples were purified by extraction with MeOH, followed by slow recrystallization through slow diffusion of diethyl ether into a saturated MDMA solution in MeOH. The crystalline samples obtained were analyzed by HPLC and the MDMA content found to be 66.2%. This value was consistent with the expected value of 4 (66.3%), i.e., the phosphate anion and MDMA were in a ratio of 1:1. The formulation of MDMA found in those tablets was therefore assigned to (HMDMA)(H 2 PO 4 ), the dihydrogen phosphate salt of MDMA.
Of the cases being studied in 2001, there were a total of 31 cases containing 292 tablets in red, green, or blue and bearing the same impressed logo of "HQ" on both sides. They were found to contain only MDMA dihydrogen phosphate 4 as the principal drug based on GC-MS analysis. In these cases, it was found that the MDMA content was within the 36 to 43% range (see Table 5 ). Again, the TIC profiles for all three colored "HQ" tablets displayed similar patterns as shown in Fig. 11 . Hence, regardless of the difference in color, the similar chemical profiles (phosphate salt as a counter anion of crystallization, detection of MDP and N-formyl-MDMA, and similar TIC profiles based on GC-MS analysis) of all these tablets suggested that they could have associated with a common origin. The unusual occurrence of 4 and the detection of these synthetic impurities further suggested that in these tablets MDMA could have been produced by a common synthetic route using MDP2P to produce MDMA via the Leuckart reaction.
Conclusions
Intelligence studies solely based on physical appearance of ecstasy tablets are insufficient. The present work demonstrated the use of chemical profiling, collectively using the active ingredient(s) found, quantitative data; other drugs present; the synthetic impurities; and the salts of crystallization of MDMA (e.g., phosphate salt of MDMA) in correlating tablets with similar chemical profiles, whether or not they bear the similar physical appearances. It can also provide such information as different consignments of tablets produced, and plausible synthetic routes. While extensive correlation of all the cases received by this laboratory using chemical profiling is beyond the scope of the present work, the latter nevertheless forms the basis of analytical profiling of illicit drugs. We envision that chemical profiling will be beneficial to the law enforcement agencies for intelligence purpose in tracing the source of ecstasy tablets. Similar studies on MA tablets are currently in progress.
